Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AiCuris Anti-infective Cures AG
With
FHI 360
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult, Immunocompetent men and women in good health of any ethnic group
History of recurrent episodes of genital herpes for at least 12 months
Seropositive for Herpes Simplex Virus HSV Type 2
Body Mass Index (BMI) between 18 and 35 kg/m2
You may not be if
Present episode of genital herpes
Intake of systemic drug against HSV or any topical application against HSV within 7 days before randomization for the trial
Intake of systemic corticosteroids, other immunomodulating agents or any investigational agent within 3 months before randomization for the trial
Positive results in any of the virology tests for human immunodeficiency virus antibody (HIV-Ab), hepatitis C antibody (HCV-Ab), hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc-Ab)
Clareo Health | Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
